BPC-157 Oral (Stable Arginate Salt)

BPC-157 Arginate is the stable arginine salt form of the pentadecapeptide BPC-157 (sequence GEPPPGKPADDAGLV, MW ~1419 Da as the free peptide). The arginate salt complex has a molecular weight of approximately 1593 Da, incorporating one L-arginine molecule (MW ~174 Da) ionically bound to the peptide's acidic residues. This salt formation serves a critical purpose: it confers resistance to acid hydrolysis in the gastric environment (pH 1.5-3.5), where standard peptide bonds are rapidly cleaved by pepsin and hydrochloric acid. Stability studies have demonstrated that the arginate salt maintains structural integrity and bioactivity after 3+ hours of exposure to simulated gastric fluid, compared to near-complete degradation of unprotected peptides within 15-30 minutes.

The oral delivery route for BPC-157 is particularly significant because this peptide was originally isolated from human gastric juice. It is a fragment of a larger protein called Body Protection Compound, which the stomach lining (gastric mucosa) naturally produces to maintain epithelial integrity, regulate mucosal blood flow, and coordinate repair processes in the GI tract. Delivering BPC-157 orally allows it to exert its effects at the site of its natural origin: the gastric and intestinal epithelium. Upon oral administration, the arginate salt dissociates in the neutral-to-alkaline pH of the upper intestine, releasing free BPC-157 that interacts directly with mucosal epithelial cells, enteric neurons, and submucosal vasculature.

The mechanism of action of oral BPC-157 involves multiple targets in the GI tract. It upregulates expression of tight junction proteins (occludin, claudin-1, ZO-1) in intestinal epithelial cells, directly addressing the molecular defect in intestinal hyperpermeability (leaky gut). It promotes mucosal angiogenesis through VEGF upregulation, ensuring adequate blood supply to healing tissue. It modulates the enteric nervous system and vagal afferent signaling, influencing the gut-brain axis and potentially affecting mood, anxiety, and central dopamine/serotonin systems. It also upregulates EGF receptor expression on intestinal epithelial cells, enhancing the proliferative response to endogenous growth factors.

Research evidence for oral BPC-157 is substantial. Sikiric et al. (Journal of Physiology-Paris, 1999) established that oral BPC-157 heals gastric ulcers with an ED50 of approximately 10 ng/kg, making it active at extraordinarily low doses. Studies in inflammatory bowel disease (IBD) models have shown that oral BPC-157 reduces colonic inflammation scores by 50-70%, restores tight junction protein expression, and reduces pro-inflammatory cytokine levels (TNF-alpha, IL-6, IL-1beta) in colonic tissue. NSAID cytoprotection studies demonstrate that oral BPC-157 administered concurrently with indomethacin or diclofenac prevents the formation of gastric and intestinal lesions that these drugs normally produce. Alcohol-induced gastropathy models show similar protection, with BPC-157 preventing ethanol-induced mucosal erosions and hemorrhagic lesions.

Systemic effects from oral administration have been confirmed in multiple studies. Oral BPC-157 promotes tendon and ligament healing at comparable efficacy to parenteral administration, suggesting meaningful systemic absorption through the GI mucosa. The mechanism of absorption is not fully characterized but likely involves paracellular transport and possibly transcytosis across intestinal epithelial cells. Once absorbed, the peptide distributes systemically and exerts the same VEGF/EGF upregulation, NO modulation, and FAK-paxillin pathway activation documented for injectable BPC-157.

The capsule format (500 mcg per capsule) provides convenient, standardized dosing. Each capsule contains the BPC-157 arginate salt in a gelatin or HPMC capsule with appropriate excipients. Store at room temperature (15-25C), protected from moisture and light. The capsule format is inherently more stable than reconstituted peptide solutions because the arginate salt is maintained in its dry state until ingestion. Shelf life is 18+ months when stored properly. No reconstitution or refrigeration is required, making this the most convenient format for BPC-157 research.

The safety profile of oral BPC-157 mirrors that of injectable BPC-157, with the added advantage that oral peptides generally have lower systemic exposure and therefore lower risk of systemic side effects. No adverse effects have been reported in published oral dosing studies across the dose ranges tested. The peptide has not demonstrated mutagenicity, teratogenicity, or organ toxicity in preclinical safety assessments. As a fragment of an endogenous gastric protein, BPC-157 is recognized by the GI immune system as a self-peptide, minimizing the risk of immune-mediated adverse reactions.